Otezla 30 MG tablet 60S
Ended Awarded Last action
- Contract number
- SPE2DR26FDA3G
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $16,587
Award facts
- Contract value 100% obligated
- $16,587.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
This delivery order, awarded January 16, 2026, by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, provides for the supply of Otezla 30 mg tablets (60-count units) with a firm fixed price ceiling value of $16,587.00 and an ultimate completion date of January 20, 2026. The award represents a competitively awarded, non-set-aside procurement executed under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 through December 2026. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor, with parent company Cencora, Inc. (doing business as AmerisourceBergen) holding the underlying IDC framework. Otezla is an oral immunosuppressant medication primarily prescribed for psoriatic arthritis, psoriasis, and Behçet's disease, and this delivery order supports the medical supply requirements of the Defense Health Agency and military treatment facilities.
This procurement demonstrates DLA's reliance on established pharmaceutical prime vendor relationships to efficiently fulfill essential medication needs across the military healthcare system. The short performance window and modest order value reflect the delivery order mechanism's flexibility in fulfilling routine pharmaceutical replenishment requirements under the broader IDC structure. As AmerisourceBergen continues to compete for potential multi-award opportunities under DLA's planned Pharmaceutical Prime Vendor Global Program Generation V initiative, this award exemplifies the company's established capability and performance history in meeting federal military healthcare pharmaceutical supply demands on a firm fixed-price basis.
Quick answers
Who was awarded contract SPE2DR26FDA3G?
SPE2DR26FDA3G was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 16, 2026.
How much is contract SPE2DR26FDA3G worth?
The government has obligated $16,587 on SPE2DR26FDA3G.
Is contract SPE2DR26FDA3G an order under another contract?
Yes. SPE2DR26FDA3G is a delivery order under SPE2DR25D1100, an indefinite delivery contract.
Was contract SPE2DR26FDA3G competed?
The extent of competition for SPE2DR26FDA3G was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award